European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors
D. Panousis1, E. Patsouris2, E. Lagoudianakis6,*, A. Pappas6, V. Kyriakidou3, Z. Voulgaris4, G. Xepapadakis1, A. Manouras6, A.M. Athanassiadou5, P. Athanassiadou5
1 Department of Breast Surgery, Iaso General Hospital
2 Department of Pathology, Athens University Medical School
3 Department of Cytology, Iaso General Hospital
4 Alexandra Hospital, 1st Obstetrics and Gynecology Department, Athens University Medical School
5 1st Pathology Department, Cytology Unit, Medical School, University of Athens
6 1st Department of Propaedeutic Surgery, Hippokrateio Hospital, University of Athens, Athens (Greece)
Eur. J. Gynaecol. Oncol. 2011, 32(2), 156–159;
Published: 10 April 2011
Introduction: The immunocytochemical expression of topoisomerase II alpha (TOP2A), enhancer of zeste homologue 2 (EZH2) and paxillin has recently gained increasing attention. Although previous studies have commented on the clinical usefulness of these markers, their role remains controversial. Aim: The purpose of the study was to investigate the expression of TOP2A, EZH2 and paxillin in relation to classic prognostic parameters and their significance as prognostic markers in imprints of resected breast carcinomas. Methods: Imprint smears from 55 patients who underwent surgical treatment for primary carcinoma in our department between 2005 and 2006 were studied immunocytochemically with the use of TOP2A, EZH2 and paxillin antibodies. Results: The expression of TOP2A correlated with higher histologic grade, tumor size and negative PR expression. High intensity staining for EZH2 expression was associated with higher histologic grade, negative ER and PR expression and positive Ki-67 expression. The expression of paxillin showed no correlation with estrogen/progesterone and HER2 expression nor with tumor grade and stage. Conclusion: Our data indicate that TOP2A and EZH2 expression are related to a more aggressive tumor phenotype. The expression of paxillin failed to correlate with any of the studied clinicopathologic factors. Further studies are needed to verify these results.